13 completed, 3 terminated, 1 unknown, 1 withdrawn. 18 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 13, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow Facet Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension Cardene® I.V. - Hypertension | Phase 2 | Withdrawn | Facet Biotech | 2007-09-01 | 2012-03-16 | |
| A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Volociximab - Ovarian Cancer, Peritoneal Neoplasms | Phase 2 | Terminated | Facet Biotech | 16 | 2007-08-01 | 2012-08-23 |
| Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study visilizumab - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Facet Biotech | 25 | 2006-08-01 | 2012-03-12 |
| A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis visilizumab - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Facet Biotech | 127 | 2006-02-01 | 2012-03-12 |
| Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease Visilizumab - Crohn's Disease | Phase 2 | Completed | Facet Biotech | 18 | 2005-02-01 | 2012-03-07 |
| Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease Visilizumab - Crohn's Disease | Phase 2 | Completed | Facet Biotech | 18 | 2005-02-01 | 2012-03-07 |
| Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis Visilizumab - Severe Ulcerative Colitis | Phase 1 / Phase 2 | Completed | Facet Biotech | 144 | 2004-01-01 | 2012-03-09 |
| Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis Daclizumab - Ulcerative Colitis, Gastrointestinal Disease | Phase 2 | Completed | Facet Biotech | 150 | 2003-04-01 | 2009-07-20 |
| A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease anti-Interferon-gamma monoclonal antibody - Crohn's Disease, Colitis | Phase 2 | Completed | Facet Biotech | 175 | 2002-03-01 | 2012-03-13 |
| Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease Visilizumab - Graft-vs-Host Disease | Phase 2 | Unknown | Fred Hutchinson Cancer Center | 80 | 2002-03-01 | 2005-06-24 |
| Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease Visilizumab - Graft vs Host Disease | Phase 1 / Phase 2 | Completed | Facet Biotech | 34 | 2002-03-01 | 2012-03-13 |
| Research Study in Patients With Severe Ulcerative Colitis Visilizumab - Ulcerative Colitis | Phase 2 / Phase 3 | Completed | Facet Biotech | 20 | 2002-03-01 | 2012-03-07 |
| Study of Daclizumab in Patients With Chronic, Persistent Asthma Daclizumab - Asthma | Phase 2 | Completed | Facet Biotech | 120 | 2001-09-01 | 2012-03-13 |
| Pilot Study in Patients With Symptomatic Steroid-Naive Asthma anti-IL-4 monoclonal antibody (pascolizumab) - Asthma | Phase 2 | Completed | Facet Biotech | 120 | 2001-08-01 | 2012-03-07 |
| Prevention of Diabetes Progression Trial (PDPT) Zenapax - Newly Diagnosed With Type 1 Diabetes | Phase 2 | Completed | Indiana University | 40 | 2000-07-01 | 2020-08-11 |
| To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris Daclizumab, NB-UVB - Psoriasis | Phase 1 / Phase 2 | Completed | Rockefeller University | 6 | 1997-10-01 | 2009-03-25 |
| To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris Daclizumab, Cyclosporine, cyclosporine and Daclizumab - Psoriasis | Phase 1 / Phase 2 | Completed | Rockefeller University | 20 | 1997-10-01 | 2009-03-13 |
| Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS Sevirumab, Foscarnet sodium, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 167 | 2021-11-01 |
Colitis, Ulcerative (5) · Crohn Disease (3) · Gastrointestinal Diseases (3) · Asthma (2) · Colitis (2) · Digestive System Diseases (2) · Graft vs Host Disease (2) · Intestinal Diseases (2) · Psoriasis (2) · AIDS-Related Opportunistic Infections (1) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Ovarian Epithelial (1) · Colonic Diseases (1) · Cytomegalovirus Retinitis (1) · HIV Infections (1)
visilizumab (8) · Daclizumab (5) · Cyclosporine (1) · Foscarnet (1) · Ganciclovir (1) · sevirumab (1) · volociximab (1)
United States (18) · Canada (5) · Belgium (3) · Australia (2) · Austria (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Israel (2) · Netherlands (2) · Norway (2) · Ukraine (2) · Croatia (1) · Italy (1)
James Krueger, MD, PHD (2) · Borucki M (1) · C. William Helm, MD (1) · Carolyn Matthews, MD (1) · Dana Glenn, MD (1) · Deborah Armstrong, MD (1) · Eric Winquist, MD (1) · Ernst Lengyel, MD (1) · Gnann J (1) · Hirsch MS (1) · James Burke, MD (1) · John Glaspy, MD (1) · Krish Tewari, MD (1) · Mark D Pescovitz, M.D. (1) · Mark Einstein, MD (1)
PMID 15498605, PMID 17920064, PMID 18787222, PMID 19714757, PMID 20947884